Although these cross-sectional studies elucidated the differences in the spatial distribution of NFTs between patients with AD and healthy controls (HCs), no reports exist on the longitudinal changes in the spatial distribution of tau deposition in the human brain. The gene discussed is MAPT; the disease is Alzheimer disease.